During the past decade, National Cancer Center Hospital; Urology conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 2 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "National Cancer Center Hospital; Urology" are "Bladder Cancer" (1 trials) and "Carcinoma, Transitional Cell" (1 trials). Many other conditions were trialed in "National Cancer Center Hospital; Urology" in a lesser frequency.

Most popular intervention types in "National Cancer Center Hospital; Urology" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (1 trials), "Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody" (1 trials), "Docetaxel" (1 trials), "Paclitaxel" (1 trials) and "Vinflunine" (1 trials). Other intervention names were less common.

The vast majority of trials in "National Cancer Center Hospital; Urology" are 2 trials for "All" genders.

Currently, there are NaN active trials in "National Cancer Center Hospital; Urology". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in National Cancer Center Hospital; Urology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in National Cancer Center Hospital; Urology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".